Immunotherapeutic Biologic Agents in Autoimmune and Autoinflammatory Diseases

References

• Afif W, Loftus EV, Faubion WA. (2010). Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol, 105, 1133–9
   PubMed Web of Science ®Google Scholar
• Aksentijevich I, Galon J, Soares M, et al. (2001). The TNF receptor associated periodic syndrome: New mutations in TNFRSF1A, ancestral origins, genotype–phenotype studies and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Gen, 69, 301–14
   PubMed Web of Science ®Google Scholar
• Albani S, Wedderburn LR, Prakken B. (2016). Adaptive immunity and autoimmunity: Translation from bench to bedside. In: Petty R et al., ed. Textbook of pediatric rheumatology. 7th Edition. Philadelphia: Elsevier, 33–42
   Google Scholar
• Alshekaili J, Li C, Cook MC. (2010). Heterophile interference accounts for method-specific ds-DNA antibodies in patients receiving anti-TNF treatment. Rheumatology, 49, 891–7
   PubMed Web of Science ®Google Scholar
• Ballow M. (2014). Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol, 14, 509–15
   PubMed Web of Science ®Google Scholar
• Barron KS, Kastner DL. (2016). Periodic fever syndromes and other inherited autoinflammatory diseases. In: Petty R et al., ed. Textbook of pediatric rheumatology. 7th Edition. Philadelphia: Elsevier, 609–26
   Google Scholar
• Beck A, Wurch T, Bailly C, Corvaia N. (2010). Strategies and challenges for the next generation of therapeutic antibodies. Nature Rev Immunol, 10, 345–52
   Google Scholar
• Boyman O, Sprent J. (2012). The role of IL-2 during homeostasis and activation of the immune system. Nat Rev Immunol, 12, 180–90
   PubMed Web of Science ®Google Scholar
• Broderick L, Tourangeau LM, Kavanaugh A, et al. (2011). Biologic modulators in allergic and autoinflammatory diseases. Curr Opin Allergy Clin Immunol, 11, 355–60
   PubMed Web of Science ®Google Scholar
• Brookes MJ, Green JR. (2004). Maintenance of remission in Crohn’s disease: Current and emerging therapeutic options. Drugs, 64, 1069–89
   PubMed Web of Science ®Google Scholar
• Bulua AC, Mogul DB, Aksentijevich I, et al. (2012). Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: A prospective, open-label, dose-escalation study. Arthritis Rheum, 64, 908–13
   PubMed Web of Science ®Google Scholar
• Burch J, Onysko M. (2012). Current standards and future treatments of rheumatoid arthritis. Formulary J Modern Med Network, 1–8. Available from: www.mednetmedical.com
   Google Scholar
• Cambrosio A, Keating P. (1992). Between fact and technique: The beginnings of hybridoma technology. J Hist Biol, 25, 175–230
   PubMed Web of Science ®Google Scholar
• Cervera R, Khamashta MA, Font J, et al. (2003). Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore), 82, 299–308
   PubMed Web of Science ®Google Scholar
• Chan AC, Behrens TW. (2013). Personalizing medicine for autoimmune and inflammatory diseases. Nat Immunol, 14, 106–9
   PubMed Web of Science ®Google Scholar
• Chapman K, Pullen N, Coney L, et al. (2009). Preclinical development of monoclonal antibodies. MAbs J, 1, 505–16
   PubMed Web of Science ®Google Scholar
• Choi J, Kim ST, Craft J. (2012). The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol, 24, 651–7
   PubMed Web of Science ®Google Scholar
• Costelloe L, Jones J, Coles A. (2012). Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother, 12, 335–41
   PubMed Web of Science ®Google Scholar
• Cush JJ, Kay J, Dao KH. (2012). Does rheumatoid arthritis or biologic therapy increase cancer risk? ACR Drug Watch Quart, 4, 1–2
   Google Scholar
• Danese S, Sans M, Franco S, et al. (2006). TNF-α blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: A novel anti-inflammatory mechanism of infliximab in Crohn’s disease. J Immunol, 176, 2617–24
   PubMed Web of Science ®Google Scholar
• Dennis G, Holweg CTJ, Kummerfeld SK, et al. (2014). Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther, 16, R90. [Epub 2014 Apr 30]
   PubMed Web of Science ®Google Scholar
• Derer S, Till A, Haesler R, et al. (2013). mTNF reverse signaling induced by TNF-α antagonists involves a GDF-1 dependent pathway: Implications for Crohn’s Disease. Gut, 62, 376–86
   PubMed Web of Science ®Google Scholar
• Dewitt EM, Kimura Y, Beukelman T. (2012). Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res, 64, 1001–10
   PubMed Web of Science ®Google Scholar
• Duhem C, Dicato MA, Ries F. (1994). Side-effects of intravenous immune globulins. Clin Exp Immunol, 97, 79–83
   PubMed Web of Science ®Google Scholar
• French LE, Trent JT, Kerdel FA. (2006). Use of IVIG in toxic epidermal necrolysis and Stevens–Johnson syndrome: Our current understanding. Int Immunopharmacol, 6, 543–49
   PubMed Web of Science ®Google Scholar
• Fusunyan R, Sanderson I. (1998). Inflammatory bowel disease. In: Delves PJ, ed. Encyclopedia of immunology. Vol. 3. 2nd edition. Boston: Academic Press, 1375–81
   Google Scholar
• Gattorno M, Martini A. (2010). Treatment of autoinflammatory syndromes. Curr Opin Pediatr, 22, 771–8
   PubMed Web of Science ®Google Scholar
• Gattorno M, Martini A. (2016). Inflammation and its mediators. In: Petty R et al., ed. Textbook of pediatric rheumatology. 7th Edition. Philadelphia: Elsevier, 14–32
   Google Scholar
• Gelfand EW. (2012). Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med, 367, 2015–25
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Dailey NJ, Canna SW, et al. (2006). Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med, 355, 581–92
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Shroff SD, Wilson M, et al. (2008). A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum, 58, 2432–42
   PubMed Web of Science ®Google Scholar
• Gregersen PK, Behrens TW. (2006). Genetics of autoimmune diseases – disorders of immune homeostasis. Nat Rev Genet, 7, 917–28
   Google Scholar
• Hooper JA. (2008). Intravenous immunoglobulins: Evolution of commercial IVIG preparations. Immunol Allergy Clin North Am, 28, 765–78
   PubMed Web of Science ®Google Scholar
• Hull KM, Drewe E, Aksentijevich I, et al. (2002). The TNF receptor-associated periodic syndrome (TRAPS): Emerging concepts of an autoinflammatory disorder. Medicine (Baltimore), 81, 349–68
   PubMed Web of Science ®Google Scholar
• Imbach P, Barandun S, d’Apuzzo V, et al. (1981). High dose IVIG for ITP in childhood. Lancet, 1, 1228–2132
   PubMed Web of Science ®Google Scholar
• Jörns A, Ertekin ÜG, Arndt T, et al. (2015). TNF-α antibody therapy in combination with the T-cell-specific antibody anti-TCR reverses the diabetic metabolic state in the LEW.1AR1-iddm rat. Diabetes, 64, 2880–91
   PubMed Web of Science ®Google Scholar
• Kansal S, Catto-Smith AG. (2014). Pediatric Crohn’s disease: Epidemiology and emerging treatment options. Ped Health Med Therapeut, 5, 59–71
   Google Scholar
• Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. (2007). The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol, 5, 1424–9
   PubMed Web of Science ®Google Scholar
• Kirou KA, Gkrouzman E. (2013). Anti-interferon alpha treatment in SLE. Clin Immunol, 148, 303–12
   PubMed Web of Science ®Google Scholar
• Klatzmann D, Abbas AK. (2015). The promise of low dose IL-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol, 15, 283–94
   Google Scholar
• Kricka LJ. (1999). Human anti-animal antibody interferences in immunological assays. Clin Chem, 45, 942–56
   PubMed Web of Science ®Google Scholar
• Krishnan E, Lingala B, Bruce B, Fries JF. (2012). Disability in rheumatoid arthritis in the era of biological treatments. Ann Rheum Dis, 71, 213–18
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Haug I. (2013). Canakinumab in patients with cryopyrin-associated periodic syndrome: An update for clinicians. Ther Adv Musculoskelet Dis, 5, 315–29
   PubMedGoogle Scholar
• Lachmann HJ, Papa R, Gerhold K, et al. (2014). The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: A series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis, 73, 2160–67
   PubMed Web of Science ®Google Scholar
• Lefranc MP. (2015). IMGT® the international imMugenetics information system® Version 1.5.0 05-18-2015. Available at: http://www.imgt.org. [last accessed 25 Jul 2015]
   Google Scholar
• Liu Y, Jesus AA, Marrero B, et al. (2014). Activated STING in a vascular and pulmonary syndrome. N Engl J Med, 371, 507–18
   PubMed Web of Science ®Google Scholar
• MacLeod MKL, Anderton SM. (2015). Antigen based immunotherapy for autoimmune and allergic disease. Curr Op Pharma, 23, 11–16
   PubMed Web of Science ®Google Scholar
• Mandel MD, Miheller P, Mullner K, et al. (2014). Have biologics changed the natural history of Crohn’s disease? Dig Dis, 32, 351–9
   PubMed Web of Science ®Google Scholar
• Marks DJ, Segal AW. (2008). Innate immunity in inflammatory bowel disease: A disease hypothesis. J Pathol, 214, 260–6
   PubMed Web of Science ®Google Scholar
• Martinon F, Burns K, Tschopp J. (2002). The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of pro-IL-beta. Mol Cell, 10, 417–26
   PubMed Web of Science ®Google Scholar
• Mastrandrea LD. (2015). An overview of organ-specific autoimmune diseases including immunotherapy. Immunol Invest, 44, 803–16.
   Google Scholar
• Mayer G. (2015). Immunology – chapter one. Innate (non-specific) immunity. Available at: www.microbiologybook.org/ghaffar/innate.htm [last accessed 19 Jul 2015]
   Google Scholar
• Mayer L, Kaser A, Blumberg RS. (2012). Dead on arrival: Understanding the failure of CTLA4-immunoglobulin therapy in inflammatory bowel disease. Gastroenterology, 143, 13–17
   PubMed Web of Science ®Google Scholar
• McKeon A. (2013). Immunotherapeutics for autoimmune encephalopathies and dementias. Curr Treat Opt Neuro, 15, 723–37
   PubMed Web of Science ®Google Scholar
• Miller EA, Ernst JD. (2009). Anti-TNF immunotherapy and tuberculosis reactivation: Another mechanism revealed. J Clin Invest, 119, 1079–82
   PubMed Web of Science ®Google Scholar
• Moinzadeh P, Hunzelmann N, Krieg T. (2013). Pharmacology and rationale for imatinib in the treatment of scleroderma. J Exp Pharm, 5, 15–22
   Google Scholar
• Mulcahy AW, Predmore Z, Mattk S. (2014). The cost savings potential of biosimilar drugs in the United States. Available at: www.rand.org/content/dam/…/RAND_PE127.pdf [last accessed 25 Jul 2015]
   Google Scholar
• Mulley J, Saar K, Hewitt G, et al. (1998). Gene localization for an autosomal dominant familial periodic fever to 12p13. Am J Hum Genet, 62, 884–9
   PubMed Web of Science ®Google Scholar
• Nazi I, Kelton JG, Larche M. (2013). The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood, 122, 1946–53
   PubMed Web of Science ®Google Scholar
• Oates-Whitehead RM, Baumer JH, et al. (2003). Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev, 4, CD004000
   Google Scholar
• Ohl K, Tenbrock K. (2011). Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotech, 2011, 432595
   Google Scholar
• O’Shea JJ, Kanno Y, Chan AC. (2014). In search of magic bullets: The golden age of immunotherapeutics. Cell, 157, 227–40
   PubMed Web of Science ®Google Scholar
• Ostrov BE, Amsterdam D. (2013). The interference of monoclonal antibodies with laboratory diagnosis: Clinical and diagnostic implications. Immunol Invest, 42, 673–90
   PubMed Web of Science ®Google Scholar
• Ostrov BE, Reynolds K, Scalzi LV. (2014). Patient preferences and satisfaction in a multispecialty infusion center. Patient Pref Adherence, 8, 755–61
   PubMed Web of Science ®Google Scholar
• Ozen S, Bilginer Y. (2014). A clinical guide to autoinflammatory diseases: Familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol, 10, 135–47
   PubMed Web of Science ®Google Scholar
• Papotto PH, Marengo EB, Sardinha LR, et al. (2014). Immunotherapeutic strategies in autoimmune uveitis. Autoimmunity Rev, 13, 909–16
   PubMed Web of Science ®Google Scholar
• Pasadhika S, Rosenbaum JT. (2014). Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics, 8, 67–81
   PubMedGoogle Scholar
• Pouchot J, Arlet JB. (2012). Biological treatment in adult-onset Still’s disease. Best Pract Res Clin Rheumatol, 26, 477–87
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kyle RA, Buadi FK. (2010). Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: Implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc, 85, 945–8
   PubMed Web of Science ®Google Scholar
• Ray S, Sonthalia N, Kundu S, Ganguly S. (2012). Autoimmune disorders: An overview of molecular and cellular basis in today’s perspective. J Clin Cell Immunol, Available at: http://dx.doi.org/10.4172/2155-9899.S10-003 [last accessed 1 Aug 2015]
   Google Scholar
• Reichert J. (2015). Therapeutic monoclonal antibodies approved or in review in the European Union or United States. Available at: http://www.antibodysociety.org/news/approved_mabs.php. [last accessed 26 May 2015, 25 Aug 2015]
   Google Scholar
• Ronnblom L, Eloranta ML. (2013). The interferon signature in autoimmune diseases. Curr Opin Rheumatol, 25, 248–53
   PubMed Web of Science ®Google Scholar
• Rosman Z, Shoenfeld Y, Zandman-Goddard G. (2013). Biologic therapy for autoimmune diseases: An update. BMC Med, 11, 88–100
   PubMed Web of Science ®Google Scholar
• Rozin AP. (2004). Matters arising: Infliximab efficiency and failure. Ann Rheum Dis, 63, 751–2
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A. (2012). Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology, 51, v38–47
   PubMed Web of Science ®Google Scholar
• Ruperto N, Martini A. (2014). JIA and malignancy. Rheumatology (Oxford), 53, 968–74
   PubMed Web of Science ®Google Scholar
• Sibley CH, Chioato A, Felix S, et al. (2015). A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease. Ann Rheum Dis, 74, 1714–9
   Google Scholar
• Singh JA, Cameron C, Noorbaloochi S et al. (2015). Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and meta-analysis. Lancet, 386, 258–65
   Google Scholar
• Tanaka T, Kishimoto T. (2012). Immunotherapeutic implication of IL-6 blockade. Immunotherapy, 4, 87–105
   PubMed Web of Science ®Google Scholar
• Toulemonde G, Scoazec JY, Miossec P. (2012). Treatment with etanercept of autoimmune hepatitis associated with rheumatoid arthritis: An open label proof of concept study. Ann Rheum Dis, 71, 1423–4
   PubMed Web of Science ®Google Scholar
• Vastert SJ, de Jager W, Noordman BJ, et al. (2014). Effectiveness of first line therapy with recombinant IL-RA in steroid-naïve patients with new onset systemic JIA: Results of a prospective cohort study. Arthritis Rheum, 66, 1034–43
   PubMed Web of Science ®Google Scholar
• Vilas-Boas A, Morais SA, Isenberg DA. (2015). Belimumab in systemic lupus erythematosus. Rheum Musculoskeletal Dis, 1, e000011. doi:10.1136/rmdopen-2014-000011
   Google Scholar
• Waldmann H, Hale G. (2005). CAMPATH: From concept to clinic. Philos Trans R Soc Lond B Biol Sci, 360, 1701–11
   Google Scholar
• Williamson LM, Hull D, Mehta R, et al. (1982). Familial Hibernian fever. Q J Med, 51, 469–80
   PubMedGoogle Scholar